Manchester on the map after Government windfall

Published on Monday, 05 March 2012 15:24
Posted by Scott Buckler

The Wellcome Trust Clinical Research Facility and The Wellcome Trust Children's Clinical Research Facility (WTCRFs), at Central Manchester University Hospitals NHS Foundation Trust (CMFT) and two leading hospital trusts, working closely with The University of Manchester, have been awarded the money to carry out  research into many of the major diseases and illnesses that affect the population of Greater Manchester and the wider North West

The three Clinical Research Facilities that will receive funding are:

Central Manchester University Hospitals NHS Foundation Trust who will use the £5.5 million funding to support studies for people with diseases such as arthritis, psoriasis, depression, addiction, and diabetes.

The Christie NHS Foundation Trust who will use the £4.5million funding to support early-stage trials of treatments for people with cancer.

University Hospital of South Manchester NHS Foundation Trust who will use the £2.5million funding to support early-stage trials of treatments for people with lung diseases such as asthma, fungal infection, chronic obstructive pulmonary disease, and also food allergies.

The WTCRFs at Central Manchester University Hospitals NHS Foundation Trust will expand world class Experimental Medicine in areas of high priority and unmet need including arthritis, mental health, cardiovascular disease, diabetes, dermatology, paediatrics and genetic medicine. The WTCRFs also support the brand new £6 million NIHR Manchester Musculoskeletal Biomedical Research Unit and Translational Research Partnership in Joint and Related Inflammatory Disease in their goal of ‘Treating Arthritis: Right First Time’.

Mike Deegan, Chief Executive of Central Manchester University Hospitals NHS Foundation Trust “Congratulations to the WTCRFs team on being awarded this funding to continue their excellent work in experimental medicine. This reinforces Manchester’s strong credentials in experimental medicine and will play a key role in constant improvements to treatment for our patients.”

Professor Ian Bruce, Medical Director of the WTCRFs said “This funding from NIHR confirms the quality of work already being done in Manchester and will help us develop our vision of supporting innovation in an environment where new discoveries can be translated into human diseases to improve the health and wealth of the nation”.

Researchers believe the success of these bids reflects the scale of expertise in conducting clinical trials in NHS organisations in Manchester and the University of Manchester which collectively form MAHSC (Manchester Academic Health Science Centre).

Professor Ian Jacobs is Director of MAHSC and Vice President of the University of Manchester. He believes this is a Red Letter Day for Manchester and further enhances the reputation of the city as a leading international centre for healthcare and health science.

He explains: “An extraordinary level of collaborative joint working has been achieved which makes it possible to conduct trials of the highest quality, on a large scale in a broad range of health areas including cancer, respiratory, neurological, cardiovascular, musculoskeletal and inflammatory disorders. This funding will lead to new healthcare innovations which will be rapidly applied for the benefit of our population through the MAHSC partnership.”

Professor Dame Nancy Rothwell, President and Vice-Chancellor of The University of Manchester, said: “These important awards build on the great strengths across the University and its partner NHS Trusts and span our research from basic discovery through to patient benefit."

NHS Trusts and Foundation Trusts with clinical research facilities submitted bids for the funding, which were judged by a panel of UK experts in both medical research and in running clinical research facilities. Winning bids were selected on the basis of the quality and volume of world-class medical research they support as well as other criteria including the strength of their partnerships with universities and industry

Secretary of State for Health, Andrew Lansley says: “Both public and patients think it’s important that the NHS should support research into new treatments, and we agree. That’s why we’re investing over £100m in research facilities, nurses and technicians to help make the NHS a world-class place to do research.

“These researchers will push forward the boundaries of what is possible. These are the people and the labs where the very best new treatments will be developed for a huge range of conditions - from cancer to diabetes and heart disease. NHS patients are the ones who will see the benefit of their work.”

Professor Dame Sally Davies, Chief Medical Officer and Chief Scientific Advisor at the Department of Health says: “These are very exciting times for clinical research in the UK, and this funding is a reflection of the commitment we have to supporting world-class experimental medicine.

“The Clinical Research Facilities will play a key role in supporting advances in treatments for a wide variety of diseases and supporting collaboration with industry. Thousands of people will benefit right across the country.”

 

The views expressed in the contents below are those of our users and do not necessarily reflect the views of GovToday.

Add comment



Refresh